TherapeuticsMD reports third quarter 2026 results, notes new IMVEXXY milestone from Knight
The royalty company said Knight confirmed a 2025 sales milestone and later flagged a second milestone for 2026, while continuing to weigh strategic alternatives.
TherapeuticsMD, Inc. reported financial results for the third quarter of 2026 on November 13, 2026, describing itself as a company that owns rights to pharmaceutical royalties1.
The company said license revenue rose in the quarter, driven largely by a milestone tied to its licensee Knight. The increase was primarily attributable to Knight achieving an IMVEXXY sales-based milestone for sales in the year ended December 31, 2025, which resulted in a $365 thousand milestone payment that Knight recognized and confirmed in the third quarter of 2026.1
The company also disclosed a subsequent milestone. After the close of the third quarter, Knight told TherapeuticsMD that a net sales milestone tied to IMVEXXY sales for the year ending December 31, 2026 had been achieved, entitling the company to a payment that will be recognized as revenue in the fourth quarter of 2026.1
On the corporate front, TherapeuticsMD reiterated that it is still reviewing options. The company said it continues to evaluate strategic alternatives, which could include an acquisition, merger, other business combination, sale of assets, or other strategic transactions, though it gave no assurance of any outcome, timing, or form, and has not set a timetable for the process, saying it does not plan to disclose further developments unless it determines disclosure is appropriate.1
On its balance sheet, the company said cash and cash equivalents totaled $10.4 million as of September 30, 2026.1
TherapeuticsMD described its current business model as follows: it was previously a women's healthcare company focused on products across the female lifespan, but in December 2022 it changed its business to become a pharmaceutical royalty company that primarily collects royalties from its licensees, and it is no longer engaged in research and development or commercial operations.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.